January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
36 citations
,
March 2011 in “Nature Communications” Cells from a skin condition can create new hair follicles and similar growths in mice, and a specific treatment can reduce these effects.
3 citations
,
October 2015 in “PubMed” Finasteride may increase iris billowing risk during surgery, similar to tamsulosin.
2 citations
,
August 2014 in “PubMed” Losartan may help treat Postural Orthostatic Tachycardia Syndrome (POTS) symptoms.
April 2024 in “The Journal of experimental medicine/The journal of experimental medicine” Treg cells help repair and regenerate tissues by interacting with local cells.
20 citations
,
January 2013 in “Annals of Dermatology” Topical minoxidil successfully treated temporal triangular alopecia.
2 citations
,
October 2024 in “Pharmaceutics” Smaller particle sizes of Tetrastigma hemsleyanum powders improve their effectiveness and liver health benefits.
5 citations
,
February 2014 in “Journal of Liquid Chromatography & Related Technologies” Method accurately measures finasteride and tamsulosin in combined drug form.
September 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” A parasite-derived molecule speeds up skin healing and affects immune cell behavior without increasing scarring.
22 citations
,
May 2003 in “Planta Medica” Torilin from Torilis japonica can inhibit testosterone 5α-reductase but is less effective than finasteride.
5 citations
,
January 2023 in “Fertility and sterility” Doctors are preparing to potentially perform uterus transplants in transgender women, considering technical, hormonal, and ethical factors.
56 citations
,
August 2019 in “Clinical, Cosmetic and Investigational Dermatology” The document concludes that Telogen Effluvium is a hair loss disorder that can be assessed with the modified wash test and may be treated with clobetasol foam, with patient management being important.
2 citations
,
April 2018 in “Journal of Cosmetic Dermatology” Tumescent fluid increases scalp hair angles, which may improve hair transplant results and reduce surgeon fatigue.
4 citations
,
July 2021 in “Cancer Research and Treatment” Temozolomide improves survival in grade III glioma patients without harming quality of life.
Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.
November 2021 in “CRC Press eBooks” Telogen effluvium is a common, temporary hair loss condition often affecting young women.
35 citations
,
January 1996 in “Dermatologic clinics” Tinea capitis is a common scalp infection causing hair loss, mostly in young children.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
March 2025 in “Laboratory Investigation” Mesothelioma of the tunica vaginalis testis is rare, often high-grade, and has a median survival of about 24 months.
5 citations
,
May 2011 in “Movement Disorders” Finasteride significantly reduced tics and obsessive-compulsive symptoms in Tourette syndrome patients.
2 citations
,
May 2017 in “Endocrinology, diabetes & metabolism case reports” Lugol's solution can cause thyroid problems if used long-term for non-approved reasons.
1 citations
,
August 2025 in “Bioengineering” Combining FTSC with TSN6 peptide greatly improves wound healing.
November 2025 in “International Dermatology” Accurate diagnosis is crucial to distinguish telogen effluvium from male pattern baldness to avoid unnecessary treatments.
39 citations
,
May 2011 in “Movement Disorders” Finasteride may help reduce symptoms in male Tourette syndrome patients.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
7 citations
,
March 2023 in “Journal of Investigative Dermatology” Low-intensity ultrasound may help protect hair follicles from chemotherapy-induced hair loss.
September 2025 in “Journal of the Pakistan Medical Association” Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
July 2026 in “Journal of the American Academy of Dermatology”
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.